Value & Pricing Perspectives From ASCO, In Brief
Executive Summary
Round-up of commentary on oncology drug value and costs during the American Society for Clinical Oncology annual meeting, including value frameworks, ways to lower drug costs and payer data.
You may also be interested in...
AstraZeneca Tagrisso, Pfizer Xalkori Stand Out Among US FDA’s Single-Arm Oncology Approvals, JAMA Suggests
Only two US approvals based on single-arm trials met the European Society for Medical Oncology’s threshold for substantial clinical benefit, according to an analysis of cancer drugs approved over a decade.
ASCO Cancer Drug Valuation Tool Will Incorporate Patient Preferences
Software that physicians and patients could use to inform value assessments for cancer drugs could be available within a year.
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.